IR Banner

Press Releases

Date Title and Summary Additional Format
Sep 2, 2021
Lumos Pharma to Participate in September Investor Conferences
AUSTIN, Texas , Sept. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will participate in the H.C. Wainwright 23 rd Annual Global Investment Conference and the Cantor
Aug 5, 2021
Lumos Pharma Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Updates
• Lumos Pharma strengthens leadership team with promotion of John McKew , PhD to President, and addition of David B. Karpf , MD as Chief Medical Officer and Mark Bach , MD, PhD to Advisory Board • Screening and enrollment of OraGrowtH210 and OraGrowtH212 Trials progress AUSTIN, Texas , Aug.
Aug 3, 2021
Lumos Pharma Announces Industry Veteran, David B. Karpf, MD, has Joined the Company as Chief Medical Officer
AUSTIN, Texas , Aug. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that experienced endocrinologist and pharma executive, David B. Karpf , MD, joined the Company August 3, 2021 as
Aug 2, 2021
Lumos Pharma Announces the Promotion of COO and Chief Scientific Officer, John McKew, PhD, to President
AUSTIN, Texas , Aug. 02, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced that current Chief Operating Officer and Chief Scientific Officer, John McKew , PhD, was promoted to President of
Jul 26, 2021
Lumos Pharma Appoints Pediatric Endocrinologist Experienced in Clinical Research and Pharmaceutical Development, Mark Bach, M.D., Ph.D., to Clinical Scientific Advisory Board
AUSTIN, Texas , July 26, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Mark Bach , M.D., Ph.D., accepted his appointment to the Company’s Clinical Scientific Advisory Board (CSAB)
Jul 22, 2021
Lumos Pharma to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021
AUSTIN, Texas , July 22, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its second quarter 2021 financial results before market open on Thursday, August 5, 2021 .
Jul 20, 2021
Lumos Pharma Announces Clinical Updates
OraGrowtH210 Trial in PGHD primary outcome 6-month data now anticipated in 2H2023; treatment period to be extended to 12 months OraGrowtH212 PK/PD Trial initiated in Q2 2021; treatment period to be extended to 12 months with primary data at 6-months Cash balance as of June 30, 2021 of $107.7
Jun 28, 2021
Lumos Pharma Announces OraGrowtH212 Trial of LUM-201 in PGHD Is Open for Enrollment
Single-Center Phase 2 Trial to Study the Pharmacokinetics/Pharmacodynamics (PK/PD) and  Unique Pulsatile Mechanism of Action of LUM-201 at Two Dose Levels AUSTIN, Texas , June 28, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on
May 19, 2021
Lumos Pharma to Participate in the Jefferies Virtual Healthcare Conference
AUSTIN, Texas , May 19, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference on June 3,
May 13, 2021
Lumos Pharma to Participate in the Oppenheimer Rare & Orphan Disease Summit
AUSTIN, Texas , May 13, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.  (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will be presenting at the Oppenheimer Rare & Orphan Disease Summit on Friday, May 21, 2021 and will be
Displaying 1 - 10 of 22